IVD China last week: Revvity and ReliableMed, KingMed Diagnostics, Kindstar Globalgene and Biostate AI, Dirui

Revvity and ReliableMed Forge Strategic Partnership to Focus on Newborn Screening and Early Diagnosis of Rare Diseases

Recently, ReliableMed announced a major strategic partnership with Revvity, a global leader in health science innovation. They will jointly develop and promote the MSLivve™ solution for the screening of inherited metabolic diseases in newborns, based on ReliableMed’s fully self-developed, domestically innovated liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection system — INSPEC 9000. This collaboration marks a significant milestone as ReliableMed’s core technological platform gains recognition from an industry-leading enterprise, accelerating deep expansion into key clinical applications and contributing to the enhancement of China’s birth defect prevention and control capabilities.

ReliableMed has consistently focused on independent innovation and industrialization of clinical mass spectrometry technologies. By leveraging Revvity’s extensive global experience and comprehensive reagent portfolio in newborn and metabolic disease screening, the two companies are launching the MSLivve™ system (Model: INSPEC 9000). This LC-MS/MS system offers high cost-effectiveness, sensitivity, and stability, capable of processing nearly a thousand samples daily. It is compatible with a variety of Revvity’s existing mass spectrometry reagents for newborn screening and rare disease detection, providing strong support for the early diagnosis and prevention of birth defects.

KingMed Diagnostics and Fudan University Children's Hospital Launch Joint Lab for Translational Immunology Research

On June 12, a signing and inauguration ceremony was held at Fudan University Children’s Hospital for the "Joint Laboratory for Translational Research on Immunological Assessment Technologies," a collaboration between the hospital and KingMed Diagnostics. The laboratory will focus on addressing technological bottlenecks in the diagnosis and treatment of pediatric immune-related diseases, developing new immunological assessment methods, and promoting clinical translation and application. This initiative aims to enhance the diagnosis and treatment capabilities for pediatric immune disorders in China.

Fudan University Children’s Hospital, approved as a National Children’s Medical Center in 2017, has long been dedicated to the prevention, diagnosis, and treatment of complex and critical pediatric conditions, playing a vital role in advancing child health. Its Department of Clinical Immunology and Allergy is one of the earliest institutions in China to engage in clinical immunology, with a strong track record in both research and clinical practice. Through close collaboration with KingMed Diagnostics, the lab seeks to achieve breakthroughs in immunological assessment technology development and clinical application, further advancing pediatric medical science.

Kindstar Globalgene and Biostate AI Establish Joint Venture to Drive the Future of Precision Medicine

Recently, Kindstar Globalgene Technology, Inc., a leading provider of clinical diagnostic services, and Biostate AI, Inc., an innovative biotechnology company focused on the integration of artificial intelligence (AI) and RNA sequencing, announced the official signing of an agreement to establish a joint venture. By combining their respective core technologies and resources, the two companies aim to advance the development and application of AI-driven precision medicine solutions in China and worldwide, addressing complex diseases and promoting human health.

Tu Zanbing, Chief Operating Officer of Kindstar Globalgene, stated, “This collaboration with Biostate AI represents a powerful alliance of 'Data + Diagnostics + AI.' Kindstar Globalgene’s nationwide clinical testing network will provide Biostate AI with high-quality, structured clinical data to accelerate the training and validation of its AI models, helping overcome key challenges in the medical AI field. Meanwhile, our established ecosystem of specialist physicians will enable efficient engagement with clinical experts, optimizing algorithm design and driving the application of large-scale vertical disease models.”

Dirui Industrial and Peking Union Medical College Hospital Launch New Project in Precision Diagnosis Research for AKI

On June 12, DIRUI INDUSTRIAL CO.,LTD. (Stock Code: 300396), hereinafter referred to as “Dirui Industrial,” held a successful kick-off meeting with Peking Union Medical College Hospital for their joint research project titled “Establishment and Validation of an AKI Assessment Model Based on Routine Urinalysis.” The meeting focused on the precision diagnosis of acute kidney injury (AKI), with both parties engaging in in-depth discussions on high-quality collaboration and the future of precision medicine.

Peking Union Medical College Hospital is a benchmark institution in China, with clinical expertise and academic achievements at the forefront of the field. Dirui Industrial will mobilize company-wide resources to ensure the smooth progress of the research project, and will continue to provide technical support, particularly in hardware development. The successful convening of this kick-off meeting marks an important step for Dirui Industrial in advancing the frontier of AKI diagnostics and reinforces its commitment to innovation in precision medicine.